HCV New Drugs

This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.

Risk Of Developing Liver Cancer After HCV Treatment

  • Home
  • Newly Diagnosed With Hep C? Or Considering Treatment?
  • All FDA Approved Drugs To Treat Hepatitis C
  • Hepatitis C Genotypes and Treatment
  • Mavyret (glecaprevir/pibrentasvir)
  • Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
  • Epclusa® (Sofosbuvir/Velpatasvir)
  • Harvoni® (Ledipasvir/Sofosbuvir)
  • VIEKIRA XR/VIEKIRA Pak
  • Zepatier(Elbasvir/Grazoprevir)
  • Cure - Achieving sustained virologic response (SVR) in hepatitis C
  • HCV Liver Fibrosis
  • FibroScan® Understanding The Results
  • HCV Cirrhosis
  • Staging Cirrhosis
  • HCV Liver Cancer
  • Risk Of Developing Liver Cancer After HCV Treatment
  • Treating Elderly HCV Patients
  • Fatty Liver Disease: NAFLD/NASH
  • Current research articles on ailments that may be related to HCV
  • Is There A Natural Way To Improve Liver Fibrosis?  
  • Can Food Or Herbs Interact With Conventional Medical Treatments?

Friday, April 26, 2013

EASL- Watch: ALCOHOL'S DEADLY IMPACT

Source - ILC Press

Related - EASL: New Studies Prove Lethal Link between Alcohol, Weight and Liver Disease in Women

Also View -
Feb 20 2013- EASL-Burden of Liver Disease in Europe: Looks at leading causes of cirrhosis and primary liver cancer in Europe




Posted by HCV New Drugs at Friday, April 26, 2013
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
File Under alcohol consumption, cirrhosis, Fatty Liver, HCV News, liver disease

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

https://feedburner.google.com/fb/a/mailverify?uri=HcvNewDrugsAndLiverHealth
View Feed

Subscribe 

  • ►  2020 (3)
    • ►  January (3)
  • ►  2019 (112)
    • ►  December (1)
    • ►  March (11)
    • ►  February (43)
    • ►  January (57)
  • ►  2018 (689)
    • ►  December (18)
    • ►  November (87)
    • ►  October (62)
    • ►  September (46)
    • ►  August (36)
    • ►  July (23)
    • ►  June (44)
    • ►  May (60)
    • ►  April (103)
    • ►  March (85)
    • ►  February (59)
    • ►  January (66)
  • ►  2017 (898)
    • ►  December (42)
    • ►  November (56)
    • ►  October (104)
    • ►  September (81)
    • ►  August (74)
    • ►  July (90)
    • ►  June (52)
    • ►  May (53)
    • ►  April (105)
    • ►  March (94)
    • ►  February (85)
    • ►  January (62)
  • ►  2016 (525)
    • ►  December (15)
    • ►  November (73)
    • ►  October (43)
    • ►  September (53)
    • ►  August (41)
    • ►  July (42)
    • ►  June (28)
    • ►  May (54)
    • ►  April (60)
    • ►  March (37)
    • ►  February (40)
    • ►  January (39)
  • ►  2015 (546)
    • ►  December (27)
    • ►  November (53)
    • ►  October (46)
    • ►  September (41)
    • ►  August (42)
    • ►  July (24)
    • ►  June (49)
    • ►  May (53)
    • ►  April (59)
    • ►  March (59)
    • ►  February (37)
    • ►  January (56)
  • ►  2014 (613)
    • ►  December (29)
    • ►  November (64)
    • ►  October (62)
    • ►  September (17)
    • ►  August (51)
    • ►  July (28)
    • ►  June (38)
    • ►  May (73)
    • ►  April (87)
    • ►  March (60)
    • ►  February (45)
    • ►  January (59)
  • ▼  2013 (957)
    • ►  December (44)
    • ►  November (77)
    • ►  October (71)
    • ►  September (71)
    • ►  August (73)
    • ►  July (84)
    • ►  June (86)
    • ►  May (78)
    • ▼  April (110)
      • Vertex Reports First Quarter 2013 Financial Result...
      • Cost will limit uptake of off-label Gilead/Bristol...
      • Frequently used biologic agents might cause acute ...
      • Top Officials Implicated in Organ Harvesting in China
      • EASL 2013: 'Quad' HCV Tx Works but No More Trials ...
      • Faldaprevir/peginterferon/ribavirin improved SVR, ...
      • Gilead Receives Complete Response Letters from U.S...
      • BioLineRx Enrolls First Patient in Phase I/II Tria...
      • EASL- MK-5172 : New Drug Holds Promise in Hepatitis C
      • Hepatitis C - Will physicians go off label, and pr...
      • EASL: PI-Based Triple Therapy Improves Virological...
      • EASL 2013 Highlights - CCO's independent conferenc...
      • EASL: Liver Imaging Tests Vie to Replace Biopsy
      • Hepatitis C: Closing in on its viral origins
      • EASL: Anemia Top Side Effect of HCV Antivirals
      • New Drug Stimulates Immune System to Kill Infected...
      • EASL- Watch: ALCOHOL'S DEADLY IMPACT
      • EASL 2013: Watch - NEW PATHS FOR CIRRHOSIS TREATMENT
      • EASL 2013- Watch: HCC, NAFLD and NASH
      • EASL - Novel screening tests for liver cancer
      • EASL - Interferon-free, triple-DAA regimen safe, e...
      • New antiviral drugs clear Hepatitis C in patients ...
      • EASL: INCIVO® Receives Positive Opinion from(CHMP)...
      • EASL: Idenix Reports Favorable Resistance Profile ...
      • EASL: Therapy Free of Side Effects of Other HCV Drugs
      • EASL: SCYNEXIS Presents SCY-635 Data on HCV at Int...
      • Sunshine hormone, vitamin D, may offer hope for tr...
      • EASL: Watch - HEPATITIS C - EXISTING TREATMENTS
      • EASL: Watch HEPATITIS C - NEW DAA's READY FOR PRIM...
      • Survey Highlights High Levels of Discrimination Ex...
      • EASL: New Studies Prove Lethal Link between Alcoho...
      • EASL: New Advances in The Management of Patients w...
      • EASL: Novel Therapeutic Approches to Cure Chronic ...
      • EASL: New Data Showed High Viral Cure Rates with 1...
      • Decline in Pulmonary Function during Chronic Hepat...
      • Medivir: Marketing Authorization Application for S...
      • EASL: Direct-acting antivirals now ready for prime...
      • EASL- Phase 2b Interferon-Free Combination Studies...
      • EASL - Probiotics Found to Reduce Hepatic Encephal...
      • EASL 2013- Tips For Viewing Hepatitis C Abstracts
      • EASL-New Advances in The Management of Patients wi...
      • EASL: Sofosbuvir - HCV Targeting Therapy Shows Mor...
      • EASL: Boehringer Ingelheim faldaprevir(BI 201335),...
      • EASL: Vertex announced new data from viral kinetic...
      • EASL: Data from Phase 3 Studies of Gilead´s Sofosb...
      • EASL: Merck to Present Interim Data on MK-5172 fr...
      • EASL: Janssen Presents New Data from Simeprevir ph...
      • EASL: Achillion Presents New Data on ACH-3102 to T...
      • EASL- Bristol-Myers oral hepatitis C regimen dacla...
      • AbbVie in race with Gilead to be first to market w...
      • MK-5172 and Daclatasvir-Merck Enters Agreement wit...
      • Simeprevir and Sofosbuvir Submitted to FDA — Clock...
      • Disease progression in chronic hepatitis C patient...
      • Hepatitis C - Watch Implications of resistance to...
      • Nursing Care for HCV Patients: Practical Strategie...
      • CDC: Infections from two foodborne germs increased...
      • A global view of hepatitis C: Physician knowledge,...
      • The Hepatitis C Drug Pipeline Report: A Groundswel...
      • IL28B testing in a rapidly changing world: Still r...
      • Mount Sinai Invents Gene Signature to Identify Ind...
      • EASL- Galectin To Present New Data On The Treatmen...
      • NanoString Secures Option from The Broad Institute...
      • Sofosbuvir plus Peginterferon and Ribavirin for Ch...
      • HCV infection alone not linked to diabetes risk
      • Achillion -1 Biotech Challenging the Hep-C Goliath
      • FDA Approves FibroScan for Noninvasive Liver Diagn...
      • Achillion Initiates Phase 2 Interferon-Free Trial ...
      • Danoprevir:Roche, Ascletis to develop & commercial...
      • Hepatitis C Newsletter: A LIVING MIRACLE
      • AASLD Podcast:Vitamin A Deficiency and Hepatitis C
      • AASLD Podcast-Sexual Transmission of Hepatitis C
      • Basic anatomy of the liver: Clinical Liver Disease...
      • AASLD: Adult Patients with Ascites Due to Cirrhosi...
      • Scripps Research:Findings Suggest a New Approach t...
      • Review: NS5A Inhibitors in the Treatment of Hepatitis
      • Treatment of hepatitis C virus infection in the fu...
      • Review Article: The Treatment of Genotype 1 Chroni...
      • HCV-infected patients bury heads in sand
      • Depression in HCV Often Resolves After Interferon ...
      • Sofosbuvir: Oral Hepatitis C Cure on Its Way-Inves...
      • UnitedHealth units hit with $500 million verdict i...
      • Hepatitis C Virus Infection: Looking for Interfero...
      • Gilead Submits New Drug Application to U.S. FDA fo...
      • EASL-Idenix will present data on IDX719
      • Is It Time to Write a Prescription for Coffee? Cof...
      • EASL- Transgene to Present New Data on TG1050 and ...
      • EASL-Bristol-Myers Squibb to Present New Data on H...
      • EASL-Merck to Present New Data on VICTRELIS® (boce...
      • EASL-Boehringer Ingelheim will announce pivotal Ph...
      • EASL-Medivir: Data from Simeprevir in Hepatitis C ...
      • Sofosbuvir/ Ledipasvir -An ‘apocalypse moment’ for...
      • Severe adverse events during antiviral therapy in ...
      • VX-135/daclatasvir: Vertex signs agreement with Br...
      • Hepatitis C Virus Vaccines in the Era of New Direc...
      • Hepatitis C Viral Load Fluctuates Without Treatment
      • Oklahoma Dental Association Issues Statement on In...
      • Role for Radiation in Locally Advanced Liver Cancer
      • Davidson County couple Donates Life
      • Management of patients with complications of cirrh...
      • Monogamous heterosexuals unlikely to transmit Hepa...
    • ►  March (70)
    • ►  February (79)
    • ►  January (114)
  • ►  2012 (1293)
    • ►  December (80)
    • ►  November (114)
    • ►  October (114)
    • ►  September (95)
    • ►  August (100)
    • ►  July (120)
    • ►  June (125)
    • ►  May (145)
    • ►  April (134)
    • ►  March (88)
    • ►  February (64)
    • ►  January (114)
  • ►  2011 (1574)
    • ►  December (75)
    • ►  November (81)
    • ►  October (70)
    • ►  September (83)
    • ►  August (142)
    • ►  July (157)
    • ►  June (166)
    • ►  May (128)
    • ►  April (160)
    • ►  March (176)
    • ►  February (140)
    • ►  January (196)
  • ►  2010 (672)
    • ►  December (184)
    • ►  November (236)
    • ►  October (223)
    • ►  September (29)

Labels

(Sofosbuvir) now Sovaldi 2017 Digestive Disease Week 2017 EASL-AASLD joint meeting on Alcohol related Liver Disease 2017 World Hepatitis Summit 2017 - International AIDS Society (IAS) 2017 British and Irish Gastroenterology meeting 2017 CROI 2017 Conference on Retroviruses and Opportunistic Infections (CROI) 2017 Drug-Induced Liver Injury Conference 2017 EASL Clinical Practice Guidelines on the management of hepatitis B virus infection 2017 GUIDE TO HEPATITIS C TESTING 2017 Gastroenterological Society of Australia Australian Gastroenterology Week 2017 IDWeek 2017 International Conference on Viral Hepatitis (ICVH) 2017 International Liver Cancer Association Annual Conference 2017 International Liver Congress 2017 International Liver Transplantation Society Consensus Statement on Hepatitis C Management in LT Candidates 2017 Practice update for managing patients cured of HCV infection 2017 Summary International Liver Congress 2017 TAG Pipeline Report 2017 The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017 2017 World Hepatitis Day 2017-10th Paris Hepatitis Conference 2017-APASL 2017-Hepatitis A to E 2017-National Strategy for the Elimination of HBV HCV 2017-WHO Essential Medicines List 2017-World Hepatitis summit 2017/WHO Global hepatitis report 2017/WHO guidelines on testing for chronic HBV and HCV infection 2018 2018 - Eliminating Hepatitis C in England 2018 - Conference on Retroviruses and Opportunistic Infections (CROI) 2018 - International Liver Congress 2018 - adult 2018 - updated and evidence-based review about Hepatocellular Carcinoma 2018- 11th Paris Hepatology Conference 2018-Diagnosis & management of hepatitis C infection 2018-WHO Access to hepatitis C treatment AASLD 2017 updated hepatitis C practice guidelines AL-335 Acetaminophen Safety Adherence to therapy BCX5191 Bavituximab Behind the Headlines Big Pharma Brain CC-31244 CDC COPD Canada Colloidal silver Complementary and Alternative Medicine Counterfeit drugs Cryoglobulinemia Daklinza(Daclatasvir) Daklinza(Daclatasvir) with sofosbuvir Dental Depression Digestion Drug Assistance Programs Epclusa® Epclusa® (Sofosbuvir/Velpatasvir) FDA Fatigue-Cognitive Function-Sleep Quality Fatty Liver Fatty Liver-RP103 Fatty liver CF102 Foodborne illness GS-7977 now Sofosbuvir GS-7977 now Sofosbuvir and simeprevir (TMC435) GS-7977 now Sofosbuvir Plus Riba GS-7977 now Sofosbuvir off label use GS-7977 now Sofosbuvir-FDA Review GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir GS-7977 now sofosbuvir / GS-5885 now ledipasvir Generic sofosbuvir-based Glecaprevir/Pibrentasvir Grazoprevir/Elbasvir (MK-5172/MK-8742) plus sofosbuvir HALT-C HBV/HCV dual infection HCC during and after direct-acting antiviral therapy in patients with hepatitis C HCV Australia HCV Awareness HCV Awareness-screening strategies HCV Baby Boomers HCV News-monthly rewind HCV News-weekly rewind HCV Self-management HCV Vaccine HCV Vaccine-TG4040 (MVA-HCV) HCV Worldwide HCV Worldwide Asia Australia Egypt HCV Worldwide-Egypt HCV Worldwide-Europe Canada Israel HCV agents/drug interactions HCV cardiovascular disease HCV diet HCV generics HCV next HCV pregnancy HCV research HCV symptoms HCV tests HCV transmission FAQ HCV vaccine GI-5005 HCV-Editorial HCV-Education HCV-Insulin resistance HCV-Statins HCV-elderly HCV/HBV/HIV special populations HEV HIV HIV-children HIV/HCV Harvoni patient assistance Harvoni® (Ledipasvir/Sofosbuvir) Healthy you History of HCV IL28B IV drug use Investment News HCV Drugs Joint pain Lichen Planus Liver Abscess Liver Cancer Treatment Liver Cysts Liver Fibrosis Liver Injury Dietary Supplements Liver Pain MAVIRET (glecaprevir/pibrentasvir) MK3(MK-3682/grazoprevir/ruzasvir1) Mavyret (glecaprevir/pibrentasvir) Medicaid Mediterranean diet Memorial Wall Men and HCV Milk thistle Miracle Mineral Solution-MMS Miravirsen Morbidity-SVR Mortality Mother to a Child Transmission Muscle Cramps NSAID Neutropenia HCV Treatment Nonalcoholic Steatohepatitis (NASH) OLYSIO™ (Simeprevir) and Sovaldi (Sofosbuvir) OLYSIO™(Simeprevir) containing regimens OTHER INFECTIOUS DISEASE Origin Of Hepatitis Other Conditions Related To HCV Other Conditions Related To HCV-Vasculitis Other Health News PHYSICAL FINDINGS SUGGESTIVE OF CIRRHOSIS Pediatric liver disease Pharmaceuticals Porphyria Cutanea Tarda (PCT) Post Treatment Post Treatment Symptoms Questions About HCV Rebuttal over Cochrane Review of DAAs SPONTANEOUS CLEARANCE STAT-C SVR24-SVR12-SVR4 Seasonal Flu Vaccine Simeprevir Simeprevir and Daclatasvir Simeprevir now Olysio Simeprevir now Olysio FDA Approved Simeprevir now Olysio and Daclatasvir Small fiber neuropathy Sofosbuvir/Cost Sorafenib Sovaldi resistance Starting HCV Treatment Surgery in liver disease TGIF-News Review Tamiflu Tattoos Technivie The natural history of hepatitis C Timeline Hepatitis Treat All VIEKIRAX Veterans Affairs Viekira Pak Viekira Pak Prescribing Information Viekira XR Vitamin E-TE/TCP supplements Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) addiction alcohol consumption anemia antidepressants arthritis ascites bath salts-spice blood scandal cancer children treating HCV chronic fatigue chronic liver failure chronic pain cirrhosis cirrhosis-Vibrio vulnificus-raw oysters cirrhosis-complications clinical trials coffee colonoscopy compensated cirrhosis decompensated cirrhosis diabetes diabetes-insulin resistance disease progression donation encephalopathy endoscopy fatigue fibromyalgia gallstones geno1 geno2 geno3 geno4 geno5 geno6 genotype test genotypes mixed genotypes;All grazoprevir/MK-8408/MK-3682 grazoprevir/elbasvir (MK-5172/MK-8742) grazoprevir/elbasvir / MK-3682 green tea hav hav vaccine hbv hbv vaccine hepatologist herb herb-kava hiv/hbv-coinfection kratom liver biopsy liver cancer liver cancer treatment-radiofrequency ablation (RFA) liver cancer/sorafenib liver disease liver function tests liver health liver/anatomy lymphoma marijuana medical tourism melatonin mental health miRNAs newly diagnosed newsletters noninvasive tests for fibrosis nonresponders null responders ombitasvir/paritaprevir/ ritonavir (OBV/PTV/r) opioid addiction partial responders platelets probiotics procrit rash recall regeneration regenerative Medicine relapse resistance to protease inhibitors response-guided therapy restless legs syndrome ribavirin salt selenium side effects side effects-direct-acting antivirals silibinin silymarin sphincter of Oddi spleen stem cell tourism stem cells stigma supplements support support-hotline svr svr durability thyroid toxicity transmission transmission-needlestick transplant transplant-MELD tylenol upper abdominal pain varices veterans video viral load vitamin A vitamin B12 vitamin D vitamin E vitamin k vitamins weekend reading wellness women zinc

Search This Blog
Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities,  editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

 On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
Latest Update Feb 12, 2019 
Lancet Study: 
Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C 
These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy 
Rebuttal over Cochrane Review of DAAs 
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.

Simple theme. Powered by Blogger.

FAIR USE NOTICE:

If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas.

It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes.

The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice